- Home
- / Immix Biopharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Immix Biopharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$1.7
2024-10-29
Market Capitalization
$46.9 M
2024-10-29
CreditSafe Score
?
Score changed on Jun 14, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|
| General and administrative expense | 1.2M | 4.0M | 7.4M | 11.4M | 13.7M |
| Operating expense total | 1.4M | 8.2M | 16.1M | 22.7M | 30.0M |
| EBIT | (1.4M) | (8.2M) | (16.1M) | (22.7M) | (30.0M) |
| Interest income | 572.0K | 1.0M | 555.5K | ||
| Interest expense | 179.9K | 497.0 | |||
| Pre tax profit | (24.4M) | (8.2M) | (15.6M) | (21.7M) | (29.4M) |
| Income tax expense | 6.0K | 10.3K | 26.4K | 41.0K | 37.7K |
| Net Income | (24.4M) | (8.2M) | (15.6M) | (21.7M) | (29.4M) |
| EPS | (0.9) | (0.8) | (0.9) |